Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | Dr. Mittie DoyleChief Medical Officer | -679,00 | 5,40k | Derivative Exercise and Sale | 8,04 - 16,00 | 3,62k | - |
| 2026-05-15 | Dr. Mittie DoyleChief Medical Officer | -3,00k | 18,33k | Derivative Exercise and Sale | 12,65 - 18,76 | 3,62k | - |
| 2026-05-07 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -18,61k | 264,99k | Derivative Exercise and Sale | 9,88 - 24,12 | 423,00 | - |
| 2026-05-06 | Mr. Paul C. VarkiChief Legal Officer | -75,06k | 573,29k | Derivative Exercise and Sale | 8,04 - 23,71 | 3,63k | - |
| 2026-05-06 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -47,00k | 570,84k | Derivative Exercise and Sale | 8,04 - 22,57 | 423,00 | - |
| 2026-05-05 | Dr. Mittie DoyleChief Medical Officer | -108,23k | 996,41k | Derivative Exercise and Sale | 8,04 - 22,88 | 3,62k | - |
| 2026-05-06 | Mr. Mitchell ChanIndependent Director | -3,17k | 72,46k | Automatic Disposition | 22,88 | 3,17k | -50,01% |
| 2026-04-29 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -16,92k | 222,59k | Automatic Disposition | 13,09 - 13,23 | 423,00 | -97,56% |
| 2026-04-06 | Dr. Mittie DoyleChief Medical Officer | -3,97k | 21,29k | Derivative Exercise and Sale | 12,65 - 18,01 | 3,62k | - |
| 2026-04-01 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -15,96k | 270,59k | Automatic Disposition | 15,86 - 17,57 | 17,34k | -47,93% |
| 2026-04-01 | Dr. Mittie DoyleChief Medical Officer | -679,00 | 5,40k | Derivative Exercise and Sale | 8,04 - 16,00 | 3,62k | - |
| 2026-03-28 | Ms. Samantha Scollard TruexIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Mr. Aaron KantoffIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Dr. Gilla KaplanIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Dr. Garry A. NeilPresident, CEO & Director | 42,97k | 0,00 | Derivative Exercise and Retained Stock | - | 90,11k | 91,16% |
| 2026-03-28 | Dr. Garry A. NeilPresident, CEO & Director | -21,89k | 304,08k | Derivative Exercise and Sale | 13,89 | 90,11k | - |
| 2026-03-28 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | 15,96k | 0,00 | Derivative Exercise and Retained Stock | - | 33,30k | 92,05% |
| 2026-03-28 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -8,24k | 114,47k | Derivative Exercise and Sale | 13,89 | 33,30k | - |
| 2026-03-28 | Mr. Mitchell ChanIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Dr. Jonathan GoldmanIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 3,17k | - |
| 2026-03-16 | Dr. Mittie DoyleChief Medical Officer | -25,49k | 116,76k | Derivative Exercise and Sale | 8,04 - 16,15 | 3,62k | - |
| 2025-12-10 | Dr. Mittie DoyleChief Medical Officer | -1,01k | 4,15k | Sale to Issuer | 4,10 | 3,62k | -21,86% |
| 2025-12-10 | Mr. Paul C. VarkiChief Legal Officer | -1,02k | 4,17k | Sale to Issuer | 4,10 | 3,63k | -21,85% |
| 2025-12-10 | Ms. Jennifer RileyChief Strategy Officer | -637,00 | 2,61k | Sale to Issuer | 4,10 | 2,66k | -19,35% |
| 2025-12-10 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -155,00 | 635,50 | Sale to Issuer | 4,10 | 17,34k | -0,89% |
| 2025-11-14 | Dr. Jonathan GoldmanIndependent Director | -8,20k | 36,63k | Derivative Exercise and Sale | 9,88 - 14,35 | 0,00 | - |
| 2025-11-14 | Dr. Jonathan GoldmanIndependent Director | -3,17k | 45,29k | Verkauf | 14,30 | 0,00 | -100,00% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
